Vizamyl FDA Approval History
Last updated by Judith Stewart, BPharm on July 1, 2025.
FDA Approved: Yes (First approved October 25, 2013)
Brand name: Vizamyl
Generic name: flutemetamol F 18
Dosage form: Injection
Company: GE Healthcare
Treatment for: Diagnosis and Investigation
Vizamyl (flutemetamol F 18) is a PET amyloid imaging agent for the evaluation of Alzheimer's disease and other cognitive disorders.
- Vizamyl is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:
- Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline.
- Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products.
Development timeline for Vizamyl
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.